The case study scenario discusses the impact of the Inflation Reduction Act (IRA) on BTKi inhibitor treatments for chronic lymphocytic leukemia (CLL) and other rare cancers. BTKi inhibitors, which treat CLL, are also approved for other rare cancers. The IRA may discourage manufacturers from pursuing additional indications, risking future research and FDA approvals. This could lead to more than 28,000 patients being at risk of receiving inferior treatments, and nearly a quarter million cancer-free life years lost over a decade for patients with conditions such as mantle cell lymphoma (MCL).
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
